Acrivon Therapeutics, Inc.
ACRVNext catalyst
ACR-368
Endometrial Adenocarcinoma
Get an email about ACRV's next catalysts
Track Acrivon Therapeutics (ACRV) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
Plus 2 more upcoming events in our data (earnings, Phase 2 readout).See the timeline
3 upcoming, 0 past
ACRV Earnings Report
Date estimated from past reporting pattern, not yet confirmed by the company | EPS Est: $-0.45 | FQ end Sep/2026 | Call: tbd
ACR-368 Phase 2 Est. Readout
Estimated primary completion for ACR-368 trial (NCT05548296) in Endometrial Adenocarcinoma. Topline data typically follows completion by weeks to months.
SourceACR-2316 Phase 2 Est. Readout
Estimated primary completion for ACR-2316 trial (NCT06667141) in Specific Advanced Solid Tumors. Topline data typically follows completion by weeks to months.
SourceMarket Overview
Stock performance and key metrics
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Frequently asked questions
What is in Acrivon Therapeutics, Inc.'s drug pipeline?→
CatalystAlert tracks 2 drug candidates in Acrivon Therapeutics, Inc.'s (ACRV) pipeline across Phase 2. Its lead program is ACR-2316 (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Acrivon Therapeutics, Inc.'s next FDA catalyst?→
Acrivon Therapeutics, Inc.'s (ACRV) next tracked catalyst is a Phase 2 readout expected Q2 2027. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track ACRV biotech catalysts?→
Add ACRV to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Acrivon Therapeutics, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.